X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Press Statements

Healthy Interactions and Merck announce launch of digital health platform designed to enhance patient engagement in diabetes management

Content Team by Content Team
17th August 2018
in Press Statements

Healthy Interactions, a global leader in health education, in collaboration with Merck , known as MSD outside the United States and Canada, announced the launch of map4health™ – a digital platform and mobile application in the U.S. that was designed to help facilitate and enhance communications between diabetes patients and educators.
This technology was developed as an extension of the Journey for Control collaboration between Healthy Interactions and Merck, and will make its debut today at the 2018 American Association of Diabetes Educators (AADE) Annual Conference in Baltimore.

Map4health is designed as a platform to help improve the quality of diabetes patient support in between in-person coaching sessions by enabling patients to connect with educators through text and video-chat, as well as providing weekly digital activities to sustain patient engagement. Patients may choose to securely log health information that their educators are able to review and respond to within the platform.

“Healthy Interactions has collaborated with Merck for over 10 years on Journey for Control to encourage patients living with diabetes to become more engaged stewards of their health,” said Paul Lasiuk, co-founder and chief executive officer, Healthy Interactions. “Today, we are proud to introduce map4health, and believe this tool will further enhance the positive impact that diabetes educators are making in the lives of their patients.”

In 2007, Healthy Interactions and Merck, also in collaboration with the American Diabetes Association (ADA), launched Journey for Control – a patient-centric education initiative targeting diabetes educators and utilizing the U.S. Diabetes Conversation Map® – to collaborate on developing tools focused on lifestyle and behavioral change to help healthcare providers improve diabetes management for people living with the disease.

“The American Diabetes Association supports technology-based methods, along with individual and group settings, for the delivery of effective diabetes self-management education and support,” according to Matt Petersen, vice president at the American Diabetes Association. “The ADA has been extremely satisfied with the ability to connect providers and patients that has been enabled through our collaboration with Healthy Interactions and Merck.”

“We are thrilled our work with Healthy Interactions will provide diabetes patients and educators a digital platform for dialogue and personalized self-management tools,” added Lisa French, associate vice president, strategy and commercial model innovation, Merck. For more information on map4health, please visit www.map4health.com.

About the Healthy Interactions and Merck Collaboration
The collaboration between Healthy Interactions and Merck began in 2007 to address unmet educational needs in diabetes management.

Map4health, launched in 2018, is an evolution of the companies’ 11-year collaboration aimed to better equip health educators to deliver improved patient support and education for patients living with diabetes. The digital tool is designed to foster communications to help patients meet their healthcare goals. The map4health platform is owned and developed by Healthy Interactions in collaboration with Merck and can be integrated into existing diabetes self-management education and support (DSMES) programs, such as Journey for Control.

About Healthy Interactions, Inc.
A global leader in health education, Healthy Interactions, Inc. is devoted to driving Personal Health Engagement—our term for helping individuals commit to healthier actions. We create powerful educational approaches that inspire valuable insights and change personal health behaviors. We build partnerships with leading medical and disease associations, not-for-profit organizations, corporations, and healthcare professionals. Our approaches enable millions of people to take control of their health and live their best lives. Our digital tools empower health care consumers to move toward their goals by providing information, tracking, and ongoing interactions with peers and health educators. The result is that patients become more active partners in their health, which improves the outcomes of their diseases. We partner with health systems and clinics across the U.S. and with pharmaceutical companies that sponsor our programs around the world.

About Merck
For more than a century, Merck, a leading global bio-pharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world – including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. For more information, visit www.merck.com

Previous Post

Eisai And Merck announce FDA approval of LENVIMA capsules for first-line treatment of Unresectable Hepatocellular Carcinoma

Next Post

U.S. FDA approves opdivo as the first new medication in nearly 20 years for certain patients with previously treated small cell lung cancer

Related Posts

Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging
Europe

Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging

3rd March 2023
Canada's National Carrier Air Canada Cargo and the Cool Tech Company ColdChase join Pharma.Aero
Manufacturing

Canada’s National Carrier Air Canada Cargo and the Cool Tech Company ColdChase join Pharma.Aero

22nd February 2023
Amyris and Immunitybio Complete Joint Venture for Next Generation Covid-19 RNA Vaccine
Drug Development

Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China

21st February 2023
Labcorp Unveils New Name for Future Independent Clinical Development Business - Fortrea
Clinical Trials

Labcorp Unveils New Name for Future Independent Clinical Development Business – Fortrea

21st February 2023
Agilent Announces New NovoCyte Flow Cytometer System Software for 21 CFR Part 11 Compliance
IPR Data Management

Agilent Announces New NovoCyte Flow Cytometer System Software for 21 CFR Part 11 Compliance

21st February 2023
Next Post

U.S. FDA approves opdivo as the first new medication in nearly 20 years for certain patients with previously treated small cell lung cancer

Latest News

Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In